Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetes.
OBJECTIVE
To determine whether exenatide is effective in reducing weight and glycosylated hemoglobin level (HbA1c), and to investigate its efficacy in improving lipid profile, blood pressure, and creatinine levels in the Arab population.


METHODS
This study was conducted at the Endocrine Unit, Dubai Hospital, Dubai, United Arab Emirates. We retrospectively collected data from patients with type 2 diabetes started on exenatide between November 2011 and February 2012. Data included demographics, clinical, laboratory results, and medications used. A general linear model adjusted by baseline characteristics (weight, HbA1C, age, use of statins, and duration of diabetes) was used to assess changes between baseline and end of trial in HbA1C, weight, low density lipoprotein cholesterol, total cholesterol, triglycerides, creatinine, and blood pressure.


RESULTS
After 6 months of treatment with exenatide, the HbA1c decreased by 0.47% (95% confidence level [CI]: -0.01 - 0.95) (p=0.055). Weight reduction was highly significant; 5.6 kg (95% CI: 3.34 - 7.85) (p&lt;0.001). Those reductions remained significant after adjustment for confounding factors.


CONCLUSIONS
This study showed that weight reduction was highly significant with exenatide. The borderline significance in HbA1c reduction can be attributed to the small sample size.
Endocrine Division, Medical Department, Dubai Hospital, PO Box 94132, Dubai, United Arab Emirates. Tel. +971 506573574. E-mail. Alaaeldin11@gmail.com.
Alaaeldin M
AM
Bashier
Elamin I
EI
Abdelgadir
Azza A
AA
Khalifa
Fouzia
F
Rashid
Sona M
SM
Abuelkeir
Fawzi E
FE
Bachet
D000328:Adult; D018912:Arabs; D001794:Blood Pressure; D008078:Cholesterol, LDL / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D000077270:Exenatide; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000378:metabolism*; D010455:Peptides / Q000627:therapeutic use*; D012189:Retrospective Studies; D014280:Triglycerides / Q000378:metabolism; D014479:United Arab Emirates; D014688:Venoms / Q000627:therapeutic use*; D015431:Weight Loss
D008078:Cholesterol, LDL; D000077270:Exenatide; D006442:Glycated Hemoglobin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D010455:Peptides; D014280:Triglycerides; D014688:Venoms; C517652:hemoglobin A1c protein, human